Business
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the IPAX-2 study[1] of TLX101-Tx (¹³¹I-iodofalan) in patients with newly diagnosed glioblastoma has completed patient enrolment. No dose-limiting toxicities (DLTs) have been observed to date, including with two doses of 5GBq (total administered activity of 10GBq), the maximum administered dose in the study.
About this update from Telix Pharmaceuticals Limited
[{"type":"list","items":[{"val":[{"type":"text","content":"IPAX-2 study of TLX101-Tx (¹³¹I-iodofalan) has completed patient enrolment.","length":75,"tagName":"p"}]},{"val":[{"type":"text","content":"Maximum dose reached with no dose-limiting toxicities observed.","length":63,"tagName":"p"}]},{"val":[{"type":"text","content":"TLX101-Tx is also the subject of a pivotal trial, IPAX BrIGHT, which is actively dosing patients with recurrent glioblastoma.","length":125,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":263,"olType":false},{"type":"text","content":"MELBOURNE, Australia and INDIANAPOLIS, May 19, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the IPAX-2 study[1] of TLX101-Tx (¹³¹I-iodofalan) in patients with newly diagnosed glioblastoma has completed patient enrolment. No dose-limiting toxicities (DLTs) have been observed to date, including with two doses of 5GBq (total administered activity of 10GBq), the maximum administered dose in the study.","length":470,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Telix Pharmaceuticals Limited)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Telix Pharmaceuticals Limited)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":166,"url":"https://media.zenfs.com/en/prnewswire.com/0260c8b822b865d6e9308370c79e16fb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Ox900w7gZ2Ce250loLbCfw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI5Mw--/https://media.zenfs.com/en/prnewswire.com/0260c8b822b865d6e9308370c79e16fb","width":400,"height":166},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/SD3MwgS94XX7Qhsvx71yeQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTI2Ng--/https://media.zenfs.com/en/prnewswire.com/0260c8b822b865d6e9308370c79e16fb","width":400,"height":166}},"href":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"IPAX-2 is an international, multicenter, open-label Phase 1 dose finding study to evaluate the safety and tolerability of TLX101-Tx in combination with post-surgical standard-of-care treatment (external beam radiation therapy and temozolomide) in primary glioblastoma. Twelve patients were enrolled into three dose escalating cohorts across four sites in Australia, Austria and the Netherlands to assess the safe...